Capital World Investors boosted its stake in shares of Unity Biotechnology Inc (NASDAQ:UBX) by 371.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,035,000 shares of the company’s stock after purchasing an additional 815,511 shares during the period. Capital World Investors owned about 2.45% of Unity Biotechnology worth $16,860,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the business. FMR LLC grew its position in shares of Unity Biotechnology by 2.5% in the 3rd quarter. FMR LLC now owns 3,562,723 shares of the company’s stock worth $56,232,000 after buying an additional 86,517 shares during the last quarter. BlackRock Inc. grew its position in shares of Unity Biotechnology by 48.1% in the 3rd quarter. BlackRock Inc. now owns 341,974 shares of the company’s stock worth $5,571,000 after buying an additional 111,039 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Unity Biotechnology by 40.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 15,705 shares of the company’s stock worth $256,000 after buying an additional 4,532 shares during the last quarter. Northern Trust Corp bought a new stake in shares of Unity Biotechnology in the 2nd quarter worth approximately $823,000. Finally, Partner Fund Management L.P. bought a new stake in shares of Unity Biotechnology in the 2nd quarter worth approximately $11,458,000. 30.12% of the stock is owned by institutional investors.
UBX has been the subject of a number of recent research reports. Mizuho assumed coverage on Unity Biotechnology in a research note on Thursday, September 6th. They set a “buy” rating and a $33.00 price objective for the company. ValuEngine lowered Unity Biotechnology from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. Morgan Stanley decreased their target price on Unity Biotechnology from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 19th. Finally, Zacks Investment Research downgraded Unity Biotechnology from a “buy” rating to a “hold” rating in a research report on Friday, October 12th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Unity Biotechnology presently has a consensus rating of “Buy” and a consensus price target of $24.80.
NASDAQ UBX opened at $16.26 on Wednesday. Unity Biotechnology Inc has a fifty-two week low of $10.33 and a fifty-two week high of $24.56.
Unity Biotechnology (NASDAQ:UBX) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.13). As a group, sell-side analysts predict that Unity Biotechnology Inc will post -1.19 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Capital World Investors Buys 815,511 Shares of Unity Biotechnology Inc (UBX)” was originally published by Modern Readers and is owned by of Modern Readers. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.modernreaders.com/news/2019/01/02/unity-biotechnology-inc-ubx-shares-bought-by-capital-world-investors.html.
About Unity Biotechnology
Unity Biotechnology, Inc, a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases.
Featured Story: What is Liquidity?
Receive News & Ratings for Unity Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Unity Biotechnology and related companies with MarketBeat.com’s FREE daily email newsletter.